Protocol Ledger

NCT05810948 · Phase II · COMPLETED

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)

Interventional Phase II clinical trial protocol NCT05810948 sponsored by argenx in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-02-21 Enrollment: 73 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05810948
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)73 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05810948
Protocol FieldVerified Registry Value
NCT IdentifierNCT05810948
Consolidated Lead Sponsorargenx
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment73 participants (ACTUAL)
Registered Start Date2023-02-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI